Cover Image
Market Research Report

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019

Published by Global Markets Direct Product code 213134
Published Content info 142 Pages
Delivery time: 1-2 business days
Price
Back to Top
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019
Published: February 1, 2019 Content info: 142 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 4, 19, 6 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11038IDB

Table of Contents

  • Introduction
  • Post-Traumatic Stress Disorder (PTSD) - Overview
  • Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development
  • Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
  • Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
  • Post-Traumatic Stress Disorder (PTSD) - Drug Profiles
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
  • Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
  • Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Anagin Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Armgo Pharma Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Artelo Biosciences Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Lixte Biotechnology Holdings Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by SpringWorks Therapeutics LLC, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top